Milestone Pharmaceuticals Revenue and Competitors

License our Company Data API

#6515

Growjo Ranking

Estimated Revenue & Valuation

Milestone Pharmaceuticals's estimated annual revenue is currently $15M per year.(i)
Milestone Pharmaceuticals received $80.0M in venture funding in October 2018.
Milestone Pharmaceuticals's estimated revenue per employee is $227,273
Milestone Pharmaceuticals's total funding is $174M.
Milestone Pharmaceuticals's current valuation is $246.1M. (January 2022)

Employee Data

Milestone Pharmaceuticals has 66 Employees.(i)
Milestone Pharmaceuticals grew their employee count by 35% last year.

Milestone Pharmaceuticals's People

Name	Title	Email/Phone
1 David Bharucha	Chief Medical Officer	Reveal Email/Phone
2 Jeff Nelson	COO	Reveal Email/Phone
3 Debbie Everidge	VP Information Technology	Reveal Email/Phone
4 Anita Holz	VP Medical Affairs	Reveal Email/Phone
5 Kim Fox	VP, Communications	Reveal Email/Phone
6 John Jackimiec	VP Market Access	Reveal Email/Phone
7 Kimberly Sheehan	VP Human Resources	Reveal Email/Phone
8 John Jackimiec	VP Market Access	Reveal Email/Phone
9 Guy Rousseau	VP Regulatory Affairs	Reveal Email/Phone
10 Roshan Girglani	VP Marketing	Reveal Email/Phone

Milestone Pharmaceuticals Competitors & AlternativesAdd Company

Competitor Name	Revenue	Number of Employees	Employee Growth	Total Funding	Valuation
#1 Aperio Clinical...	$11.2M	63	7%	N/A	N/A
#2 Pharmaceutical ...	$5099.8M	32902	-4%	N/A	N/A
#3 Triangle Biotec...	$1.7M	11	0%	N/A	N/A
#4 Onspira Therape...	$0.6M	4	-56%	N/A	N/A
#5 Inhalon Biophar...	N/A	15	7%	N/A	N/A
#6 Kiniciti	$0.9M	11	-39%	N/A	N/A
#7 Cytex Therapeut...	$1.7M	9	0%	N/A	N/A
#8 Achelios Therap...	$0.6M	3	0%	N/A	N/A
#9 Arbiom	$4.8M	31	-6%	N/A	N/A
#10 NC BioNetwork	$6.4M	36	6%	N/A	N/A

Add Company

Show More Biotech Companies

What Is Milestone Pharmaceuticals?

Milestone Pharmaceuticals Inc. is a cardiovascular drug development company developing novel small molecule therapeutics for transient cardiovascular conditions. Milestone's lead product is a potent and short-acting nasally-delivered calcium channel antagonist for the episodic treatment of paroxysmal supraventricular tachycardia (PSVT). The company's lead product, etripamil (MSP-2017), is in phase 3.

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power

$174M

Total Funding

Number of Employees

$15M

Revenue (est)

35%

Employee Growth %

$246.1M

Valuation

N/A

Accelerator

Milestone Pharmaceuticals News

2022-04-17 - Should You Hold Milestone Pharmaceuticals Inc (MIST) in Biotechnology Industry?

Should You Hold Milestone Pharmaceuticals Inc (MIST) in Biotechnology Industry? Tuesday, April 19, 2022 11:49 AM | InvestorsObserver Analysts.

2022-04-17 - Milestone Pharmaceuticals (NASDAQ:MIST) Lifted to Overweight ...

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The...

2022-04-13 - Milestone Pharmaceuticals Reports Inducement Grants Under ...

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), is a biopharmaceutical company focused on the development and commercialization of innovative...

2021-08-11 - Milestone Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Update USA - English USA - English USA - English USA - English

MONTREAL and CHARLOTTE, N.C., Aug. 11, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the second quarter ended June 30, ...